ASCO 2020: Updates in renal cancer

Bookmark and Share
Published: 5 Jun 2020
Views: 1074
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Dr Toni Choueiri speaks to ecancer about the latest developments in renal cancer from the ASCO 2020 virtual meeting.

He begins by discussing some of the studies he has been involved in, including the FRACTION-RCC study which was an assessment into the use of nivolumab plus ipilimumab for treatment-refractory advanced renal cell carcinoma.

Dr Choueiri also notes the updated analysis from the KEYNOTE-426 study where pembrolizumab plus axitinib showed superior and durable antitumour activity in comparison with sunitinib for first-line advanced renal cell carcinoma patients.